Abstract
Autoimmunity accounts for a significant percentage of human disease and remains a challenging syndrome to treat. While systemic immunosuppression can be beneficial, the associated toxicity of the pharmacologic agents necessitates an antigen-specific approach to silence, eradicate or prevent the genesis of autoreactive immune cells. Gene therapy offers the possibility of providing precise antigen-targeted therapies, thereby sparing the patient the significant toxicity associated with lifelong commitment to chemical immunosuppressives. Gene-based therapies could include, but are not limited to the manipulation of immune networks of tolerance by antigen presentig cell engineering, proinflammatory cytokine blockade using soluble antagonists expressed from viral vectors as well as modulation of immune regulatory networks. The potential utility of gene therapy strategies promoting tolerance in two model autoimmune disorders, type I diabetes mellitus and rheumatoid arthritis are discussed in this review.
Keywords: Gene Therapy, Autoimmune Disorders, MOLECULAR PLAYERS, Clonal Deletion, Immune Deviation, IDDM AND RA, Anergy
Current Gene Therapy
Title: Gene Therapy Strategies to Prevent Autoimmune Disorders
Volume: 2 Issue: 3
Author(s): Massimo Trucco, Paul D. Robbins, Angus W. Thomson and Nick Giannoukakis
Affiliation:
Keywords: Gene Therapy, Autoimmune Disorders, MOLECULAR PLAYERS, Clonal Deletion, Immune Deviation, IDDM AND RA, Anergy
Abstract: Autoimmunity accounts for a significant percentage of human disease and remains a challenging syndrome to treat. While systemic immunosuppression can be beneficial, the associated toxicity of the pharmacologic agents necessitates an antigen-specific approach to silence, eradicate or prevent the genesis of autoreactive immune cells. Gene therapy offers the possibility of providing precise antigen-targeted therapies, thereby sparing the patient the significant toxicity associated with lifelong commitment to chemical immunosuppressives. Gene-based therapies could include, but are not limited to the manipulation of immune networks of tolerance by antigen presentig cell engineering, proinflammatory cytokine blockade using soluble antagonists expressed from viral vectors as well as modulation of immune regulatory networks. The potential utility of gene therapy strategies promoting tolerance in two model autoimmune disorders, type I diabetes mellitus and rheumatoid arthritis are discussed in this review.
Export Options
About this article
Cite this article as:
Trucco Massimo, Robbins D. Paul, Thomson W. Angus and Giannoukakis Nick, Gene Therapy Strategies to Prevent Autoimmune Disorders, Current Gene Therapy 2002; 2 (3) . https://dx.doi.org/10.2174/1566523023347760
DOI https://dx.doi.org/10.2174/1566523023347760 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design Treating Diabetes Mellitus in Older and Oldest Old Patients
Current Pharmaceutical Design Role of Endogenous GLP-1 and its Agonists in Osteopenia and Osteoporosis: But We Little Know Until Tried
Current Diabetes Reviews Helicase Domain Containing Proteins in Human Disorders
Current Genomics Lipid Metabolism and Nutrient Partitioning Strategies
Current Drug Targets - CNS & Neurological Disorders The Impact of Mitochondrial DNA and Nuclear Genes Related to Mitochondrial Functioning on the Risk of Parkinson’s Disease
Current Genomics Mineralocorticoid Receptor-Associated Hypertension and Target Organ Damage: Clinical Relevance for Resistant Hypertension in End Stage Renal Disease
Current Hypertension Reviews Cross-Talk Between Adipose Tissue Health, Myocardial Metabolism and Vascular Function: The Adipose-Myocardial and Adipose-Vascular Axes
Current Pharmaceutical Design Association Between Vitamin D Serum Level and Depression
Current Psychopharmacology The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer’s Disease
Current Alzheimer Research Cerebral Microbleeds Do Not Predict Hemorrhagic Transformation in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Disturbed Homeostasis in Patients with Acute Psychosis
Current Psychiatry Reviews A Review on the Applications of Nano-medicines in Treatments of Metabolic Diseases
Recent Innovations in Chemical Engineering Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology Disparities in Cardiovascular Disease Risk in the United States
Current Cardiology Reviews The Clinical Spectrum of Nephrogenic Systemic Fibrosis
Current Rheumatology Reviews Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Pharmacological Profile of SSRIs and SNRIs in the Treatment of Eating Disorders
Current Clinical Pharmacology Protein-Tyrosine Phosphatase 1B (PTP1B): A Novel Therapeutic Target for Type 2 Diabetes Mellitus, Obesity and Related States of Insulin Resistance
Current Drug Targets - Immune, Endocrine & Metabolic Disorders